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Lichen sclerosus is a common, acquired chronic inflammatory skin disease of unknown etiology, although 
circulating autoantibodies to the glycoprotein extracellular matrix protein 1 (ECM1) have been detected in 
most patients’ sera. We have examined the nature of ECM1 epitopes in lichen sclerosus sera, developed an 
ELISA system for serologic diagnosis, and assessed clinicopathological correlation between ELISA titer and 
disease. Epitope-mapping studies revealed that lichen sclerosus sera most frequently recognized the distal 
second tandem repeat domain and carboxyl-terminus of ECM1. We analyzed serum autoantibody reactivity 
against this immunodominant epitope in 413 individuals (95 subjects with lichen sclerosus, 161 normal con-
trol subjects, and 157 subjects with other autoimmune basement membrane or sclerosing diseases). The ELISA 
assay was highly sensitive; 76 of 95 lichen sclerosus patients (80.0%) exhibited IgG reactivity. It was also highly 
specific (93.7%) in discriminating between lichen sclerosus and other disease/control sera. Higher anti-ECM1 
titers also correlated with more longstanding and refractory disease and cases complicated by squamous cell 
carcinoma. Furthermore, passive transfer of affinity-purified patient IgG reproduced some histologic and 
immunopathologic features of lichen sclerosus skin. This new ELISA is valuable for the accurate detection and 
quantification of anti-ECM1 autoantibodies. Moreover, the values may have clinical significance in patients 
with lichen sclerosus.
Introduction
Lichen sclerosus is a common acquired skin disorder (1–3). The 
typical clinical presentation consists of pale, indurated papules 
and plaques with intractable irritation. Any skin may be involved, 
but the most common site is the genitalia (85% to 98% of cases), 
although disease affecting the head, neck, scalp, palms and soles, 
area around the eye, tongue, and area around stoma sites has been 
reported (1, 3–5). Clinical and epidemiological studies suggest that 
the condition is underreported and may have a prevalence of more 
than 1 in 300 (2, 5). Females are more commonly affected than 
males; the ratio of female to male patients is as high as 10:1. Lichen 
sclerosus can occur at any age, but a bimodal peak occurs in prepu-
bertal children and then in postmenopausal women and in men 30 
to 50 years of age (1, 3).
The disease may be difficult to diagnose. It is sometimes mis-
taken for signs of child abuse in young children or for an inflam-
matory disorder such as lichen planus in adults. Currently no 
specific disease markers or diagnostic tests other than a skin biop-
sy identify this disease, although even a skin biopsy may show 
overlap with other inflammatory skin diseases. Furthermore, the 
clinical course may be protracted with only limited symptomatic 
relief from the topical application of high-dose fluorinated cor-
ticosteroids. Rarely, systemic immunosuppression (e.g., with oral 
cyclosporin) may be required for severe disease (6). Genital disease 
may also result in severe scarring, which leads to difficulty in mic-
turition and to impaired sexual activity. Some cases may also be 
complicated by malignancy (∼5%), most frequently squamous cell 
carcinoma (2, 3). Thus, lichen sclerosus represents an important 
disease process to investigate.
The etiology of lichen sclerosus is uncertain, but accumulat-
ing evidence suggests an autoimmune basis to the disorder. For 
example, some reports have described a disease association with 
HLA class II antigen DQ7-DQ9 (7, 8), as well as an increased inci-
dence of other autoimmune diseases and autoantibodies in some 
patients. Associated disorders include thyroid disease, pernicious 
anemia, diabetes mellitus, alopecia areata, vitiligo, and mucous 
membrane pemphigoid (1, 4, 9). Historically, data implicating a 
humoral autoimmune response in lichen sclerosus have been lim-
ited to a single 90-year-old case report of probable lichen sclerosus 
being induced by injection of serum from an affected individual 
into nonlesional skin (10). However, we have recently identified 
specific autoantibodies to a particular skin antigen, extracellular 
matrix protein 1 (ECM1), in sera from the majority of patients 
with lichen sclerosus (11). These data provide preliminary clues to 
unraveling the lichen sclerosus disease mechanism.
ECM1 is present within epidermis and dermis and has been 
implicated in aspects of epidermal differentiation and in protein-
Nonstandard abbreviations used: arbitrary unit (AU); area under the curve (AUC); 
confidence interval (CI); extracellular matrix protein 1 (ECM1); glutathione  
S-transferase (GST); receiver operating characteristic (ROC); Tris-buffered saline (TBS).
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protein interactions within the dermis (12, 13). The rationale for 
ECM1 as a target antigen in lichen sclerosus is supported by the 
recent identification of pathogenic mutations in the ECM1 gene in 
an inherited autosomal recessive skin disorder, lipoid proteinosis 
(OMIM 247100) (14). Histology of skin in this genetic condition 
shows considerable overlap with skin biopsy findings in lichen scle-
rosus, including disruption of basement membrane and hyaline 
(glassy) changes in the upper dermis (11, 14, 15). From a clinico-
pathologic perspective, disruption of ECM1 function by acquired 
autoantibodies or inherited gene mutations appears to contribute 
significantly to the disease pathology in lichen sclerosus or lipoid 
proteinosis, respectively. Further characterization of ECM1 anti-
bodies in lichen sclerosus may, therefore, give new insight into this 
common acquired condition.
The aim of this study was to characterize the antigenic epitopes 
within ECM1 targeted by autoantibodies in sera from patients 
with lichen sclerosus. A further goal was to develop a sensitive and 
quantitative ELISA specific for autoantibodies directed against 
ECM1. We applied this ELISA in a clinical context, to determine 
its potential utility in the serologic diagnosis of lichen sclerosus 
and to assess whether any clinicopathological correlation exists 
between the ELISA results and the clinical status of individuals 
with lichen sclerosus.
Results
Generation of recombinant ECM1 fragments for epitope mapping. 
We have recently shown that the majority of lichen sclerosus 
patients’ sera (74%) contain IgG reactivity to the three isoforms 
of the native ECM1 protein (ECM1a, ECM1b, and ECM1c), as 
well as its full-length recombinant protein (11). To more rigor-
ously identify antigenic epitopes within ECM1, we generated a 
series of bacterial recombinant fragments that cover almost the 
entire ECM1 sequence (Figure 1).
As assessed by Coomassie gel 
staining and immunoblotting with 
anti–glutathione S-transferase 
(anti-GST) antibody, the GST tag-
ging at the NH2-terminus of the 
recombinant proteins allowed for 
efficient purification of all five 
recombinants in a single step (Fig-
ure 2). Each of these recombinant 
proteins was detected at the pre-
dicted molecular mass, as a dou-
blet band, with the exception of 
multiple bands for ΔS/COOH. The 
bands with a lower molecular mass 
probably result from degradation 
products during sample prepara-
tion (e.g., after protein extraction 
or SDS treatment) or from aberrant 
migration in SDS-gel electrophore-
sis. Each recombinant protein was 
finally eluted with more than 90% 
purity and sufficient protein con-
centration (∼100 μg/ml) for subse-
quent experiments.
IgG autoantibodies from lichen scle-
rosus sera react predominantly with the 
distal COOH-terminal region of ECM1. 
We tested IgG reactivity of 39 lichen sclerosus sera against the 
newly generated ECM1 recombinant fragments by immunoblot-
ting. In this part of the study, five normal and six disease sera (three 
systemic lupus erythematosus and three bullous pemphigoid) were 
included as control subjects. The results demonstrated that lichen 
sclerosus autoantibodies recognize multiple antigenic sites located 
throughout the ECM1 molecule (Figure 3 and Table 1).
Among the sera samples from the 39 patients, 16 (41.0%) reacted 
with ΔNH2, 22 (56.4%) reacted with ΔPx/COOH, and four reacted 
with (10.3%) with ΔS/COOH. Interestingly, all the sera that react-
ed with ΔNH2 also showed reactivity to ΔPx/COOH, which sug-
gests a heterogeneous reactivity to ECM1 in lichen sclerosus sera. 
Thus, this initial screen suggested that the ΔPx/COOH fragment 
was targeted most frequently.
To further characterize the highest immunoreactivity against the 
ΔPx/COOH, we generated an additional fragment, ΔS/ex7, which 
overlaps with the NH2-terminal by 133 amino acids of ΔPx/COOH 
(Figure 1). Repeat immunoblotting with the 22 ΔPx/COOH-posi-
tive lichen sclerosus sera revealed that only one of these original 
sera showed any reactivity (albeit faint) to ΔS/ex7. These data 
indicate that the immunoreactive part of clone ΔPx/COOH lies 
between amino acids 359 and 499.
Combined with the other results that showed more than 10% of 
lichen sclerosus sera react with the COOH-terminal end of ECM1 
(ΔS/COOH), evidence indicated that the main immunodominant 
region of ECM1 was located between amino acids 359 and 559. This 
interpretation also takes note of the fact that all the sera that react-
ed with the ΔNH2 clone also reacted with the indicated region.
To further define the immunodominant region, we generated 
an extra fragment (ΔDs/COOH) specific for amino acids 359 to 
559 (Figure 1) and repeated the immunoblotting with the above-
mentioned sera (Figure 3 and Table 1). As expected, specific 
immunoreactivity was detected in the majority of lichen sclero-
Figure 1
Schematic representation of ECM1 protein and its five recombinant GST fusion fragments. The distinct 
molecular domains comprise a signal peptide, a cysteine-free NH2-terminal domain, two tandem repeat 
domains, and a COOH-terminal domain. The position of the single cysteine residues and potential N-gly-
cosylation sites are indicated. The full-length 1.8-kb ECM1 cDNA was initially divided into three different 
fragments, ΔNH2 (33 to 226 amino acids), ΔPx/COOH (226 to 499 amino acids), and ΔS/COOH (499 to 
559 amino acids), designed to span almost the entire ECM1. Two further fragments were then synthe-
sized. The ΔS/ex7 fragment encodes part of the ΔPx/COOH domain (226 to 359 amino acids), and the 
ΔDs/COOH fragment encodes the distal part of the second tandem repeat domain and COOH-terminus 
(359 to 559 amino acids). All fragments were fused with GST-encoded cDNA at the NH2-terminus of the 
recombinant proteins. The amino acid residue numbers are shown as described elsewhere (13). The 
predicted molecular weights (kDa) of each recombinant fusion fragment are shown on the right. 
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sus sera (28/39, 71.8%). Almost all the sera that were positive on 
the initial immunoblotting when any of other ECM1 recombi-
nant fragments were used remained positive when tested with 
ΔDs/COOH. None of the normal or disease control sera showed 
reactivity to any of the ECM1 recombinants. These results suggest 
that the distal second tandem repeat and COOH-terminal region 
encompassing amino acids 359 to 559 can detect almost the entire 
spectrum of antibody reactivity against ECM1 in patients’ sera.
Lichen sclerosus antibodies are directed against specific, but 
not cross-reactive, ECM1 epitopes. To determine the epitope 
specificity of lichen sclerosus antibodies, we performed indirect 
immunofluorescence on normal human skin sections. However, 
immunostaining with standard dilutions of the sera was negative 
in almost all cases, as demonstrated previously (11). This finding 
suggests that the binding affinity or the titer of the antibodies is 
extremely low. The latter assumption is supported by evidence that 
any dilution of the patients’ sera greater than 1:20 resulted in a 
loss of the specific bands when reassessed by recombinant protein 
immunoblotting (data not shown).
We therefore affinity-purified the IgG fractions from six repre-
sentative lichen sclerosus sera that were positive on immunoblot-
ting with recombinant proteins (selected sera comprised three that 
were reactive with ΔDs/COOH alone and three others that were 
reactive with both ΔNH2 and ΔDs/COOH).
Immunofluorescence staining of normal human skin with the 
affinity-purified IgG antibodies from all patients’ sera displayed 
an intracellular signal in basal keratinocytes; weaker staining 
occurred in the suprabasal keratinocytes and around dermal 
blood vessels (Figure 4B). This immunolabeling appearance was 
very similar to the staining pattern seen with anti-ECM1 rabbit 
polyclonal antibody (Figure 4A). The positive staining with the 
ΔDs/COOH-reactive sera was blocked efficiently by preabsorp-
tion with excess amounts of the ΔDs/COOH recombinant pro-
tein (Figure 4C). The positive staining with a dual ΔNH2-reactive 
and ΔDs/COOH-reactive sera was not altered or was only slightly 
diminished by preabsorption with either ΔNH2 or ΔDs/COOH 
recombinants separately (Figure 4D), but was blocked almost 
completely when preabsorbed with a mixture of ΔNH2 and ΔDs/
COOH recombinants together (Figure 4E). None of the con-
trol recombinant proteins, GST alone or BP180 NC16a, altered 
the positive staining with the affinity purified sera (Figure 4F). 
Immunolabeling did not occur with affinity-purified normal 
human control sera (data not shown). These findings indicate 
that immunoreactivity of the affinity-purified IgGs from lichen 
sclerosus is specific for ECM1, and no antibody cross-reactivity 
against other epitopes within ECM1 occurs.
A novel ELISA using the distal second tandem repeat and COOH-termi-
nal region of ECM1 detects IgG reactivity in lichen sclerosus patients’ sera. 
Sera from patients with lichen sclerosus (n = 95) and, as controls, 
from normal volunteers (n = 161), systemic lupus erythematosus 
patients (n = 70), bullous pemphigoid patients (n = 72), and system-
ic sclerosis patients (n = 15) were tested for IgG reactivity against 
the most immunodominant ΔDs/COOH fragment, immobilized 
onto an ELISA plate. The results were expressed as arbitrary units 
(AU) based on the positive and negative reference sera (1.0 and 0 
OD values in the assay, respectively).
All the sera investigated by use of this ELISA exhibited AU rang-
ing from 0 to 1.150. Based on the maximization of the Youden 
index (J = sensitivity + specificity-1), the cutoff value for the ELISA 
was established at “0.328 AU,” which corresponds to a Youden 
index of 0.77. The receiver operating characteristic (ROC) analy-
sis revealed that the diagnostic accuracy of the ECM1-ELISA for 
lichen sclerosus, as estimated by the area under the curve (AUC), 
was 0.919 (95% confidence interval [CI] 0.864 to 0.961) (Figure 5, 
inset). The mean intraplate and interplate coefficients of variation 
for the positive reference serum were 3.2% and 3.8%, respectively 
(those for the negative reference serum were 1.0% and 3.4%).
When the selected cutoff value was used, 76 of 95 lichen scle-
rosus sera showed specific reactivity with the ΔDs/COOH, which 
results in a specificity and sensitivity of 93.7% and 80.0%, respec-
tively (Figure 5). Only three sera (3.4%) yielded marginal OD 
readings. A linear correlation in the immunoreactivity against 
the ΔDs/COOH occurred between immunoblotting and ELISA, 
although the detection sensitivity in lichen sclerosus sera was 
higher by ELISA than by immunoblotting when the full-length 
ECM1 recombinant protein was used (11).
In contrast, comparative control groups did not show any signifi-
cant reactivity to the ΔDs/COOH recombinant protein (Table 2). 
Of 161 normal, healthy control subjects, 7 (4.3%; 95% CI 1 to 7) had 
Figure 2
Purification of recombinant ECM1-GST fusion proteins. The purified 
ECM1-GST fusion recombinant proteins were separated on SDS-poly-
acryl amide gel and detected by Coomassie blue staining (top). The 
identical gel was immunoblotted using anti-GST antibody (bottom). 
Molecular weights are indicated on the left column.
Table 1
Lichen sclerosus immunoreactivity against a series of ECM1-GST 
recombinant proteins on immunoblotting
Clone Reactivity of lichen sclerosus sera (n = 39)
ΔNH2 16 (41.0%)
ΔPx/COOH 22 (56.4%)
ΔS/COOH 4 (10.3%)
ΔS/ex7 1 (2.6%)
ΔDs/COOH 28 (71.8%)
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positive ECM1 reactivity. The difference between the lichen sclero-
sus group and these control subjects was statistically significant 
(P < 0.0001). For the other disease control subjects, 5 of 70 sys-
temic lupus erythematosus (7.1%; 95% CI 1 to 13), 6 of 72 bullous 
pemphigoid (8.3%; 95% CI 2 to 15), and 2 of 15 systemic sclerosis 
(13.3%; 95% CI 0 to 27) were positive. Overall, the ECM1-ELISA gave 
20 false-positive results in 318 control subjects (6.3%), although these 
false-positive sera did not belong to any particular disease group. 
However, when the cutoff value was reassessed by use of an alterna-
tive standard formula (the mean OD unit of all the normal control 
subjects + 3 SD, 0.473), 18 of 20 false-positive sera became negative, 
and only two sera from patients with systemic lupus erythematosus 
remained positive. Neither of these two sera showed any positive reac-
tivity on ECM1 recombinant immunoblot or immunofluorescence 
microscopy on normal human skin (data not shown). Therefore, 
these false-positive results might be caused by nonspecific reactivity 
(e.g., against some minor contaminants from the antigen prepara-
tion or possibly from insufficient serum blocking).
ELISA values correlate with lichen sclerosus disease severity and dura-
tion. We analyzed the two clinical subgroups, severe disease 
(n = 17) or mild disease (n = 18), with individual ELISA scores 
against ECM1 (Figure 6). A significant correlation occurred 
between disease severity and ECM1-ELISA scores; patients with 
severe clinical phenotypes had higher ELISA scores compared 
with those who had mild disease (mean ELISA score ± SD; 
0.665 ± 0.216 vs. 0.425 ± 0.129, respectively; Mann-Whitney 
U test, P = 0.031).
Interestingly, four of the severe-phenotype patients who 
suffered from lichen sclerosus complicated by squamous cell 
carcinoma on the affected skin (two of whom also had extra-
genital lichen sclerosus) exhibited higher ELISA scores overall 
(0.689 ± 0.230), although these scores did not differ signifi-
cantly from the scores of other subjects in the severe-disease 
group without malignancy or with just genital skin involve-
ment (Figure 6, filled circles and filled squares).
Apart from disease severity, the anti–ECM1-ELISA titers in 
these 35 patients and in four additional patients were assessed 
against disease duration (Table 3). Significantly lower ELISA 
scores occurred in the group who had the disease less than 1 
year compared with any of the other three groups who had 
lichen sclerosus longer than 1 year. Higher ELISA scores 
were associated with patients who had longstanding disease, 
although there were no significant statistical differences 
between ELISA scores in any of the latter three groups; that is, 
in subjects who had lichen sclerosus 1 to 5 years, 5 to10 years, 
or longer than 10 years.
Anti-ECM1 IgG from lichen sclerosus sera can access native ECM1 in 
vivo. Within 48 hours of the initial injection of each of the six affin-
ity-purified IgG from lichen sclerosus sera, the ears of mice showed 
marked swelling with erythema. The swelling persisted, and, in addi-
tion, dilated blood vessels became evident within 12 days. These 
signs became most prominent at 20 days but persisted up to the 
final assessment point (28 days) (Figure 7A, left). In contrast, no 
swelling or changes in skin vasculature were noted after injection of 
control affinity-purified IgG into the mice ears (Figure 7A, right).
Histology of the affinity-purified IgG from lichen sclerosus 
sera–injected skin sites at 4 days and 28 days showed moderate 
inflammation with edema, patchy inflammatory cell infiltration, 
and dilated blood vessels (especially at 28 days) in the upper and 
mid-dermis (Figure 7B) in comparison to the skin of control sub-
jects (Figure 7C). These changes are not specific, but are compat-
ible with the early histological features seen in lichen sclerosus. 
However, no evidence of hyalinosis or scarring, typical histologic 
features of established (late) lichen sclerosus skin pathology, is 
present Moreover, immunohistologic examination revealed that 
Figure 3
Immunoblotting for lichen sclerosus sera by use of a series of 
recombinant ECM1-GST fusion fragments. The five recombinant 
ECM1-GST fragments, ΔNH2, ΔPx/COOH, ΔS/COOH, ΔS/ex7, and 
ΔDs/COOH, were independently immunoblotted with serum sam-
ples from patients with lichen sclerosus (12 of which are illustrated) 
or control subjects. Each of the lichen sclerosus sera (numbered 
on the bottom) showed heterogeneous immunoreactivity against 
the recombinants. Note that ΔDs/COOH represents the most anti-
genic epitope recognized by the vast majority of lichen sclerosus 
sera. Representative results from each recombinant blot are shown. 
Arrows indicate the positive signals.
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all six affinity-purified sera showed IgG deposition within the 
lower epidermis (intracellular) and surrounding dilated dermal 
blood vessels (Figure 7, D–F). These changes were very similar to 
those found in ECM1 immunolabeling of normal human skin 
and in mice injected with anti-ECM1 rabbit polyclonal antibody 
(data not shown). None of the other control IgG-injected mice had 
evidence of specific IgG deposition in their skin (Figure 7, G and 
H). These findings suggest that lichen sclerosus IgG is capable of 
binding ECM1 in vivo.
Discussion
In this study, we have partially characterized the antigenic 
epitopes within the ECM1 protein that are detected by circulating 
IgG autoantibodies in the sera of most 
patients with lichen sclerosus. We have 
also established a novel ELISA system 
that may be useful in providing a diagnos-
tic marker of the disease and an indicator 
of clinical severity in affected individuals. 
Our large cohort study demonstrates that 
the ELISA using the recombinant pro-
tein that spans the distal second tandem 
repeat domain and COOH-terminus of 
ECM1 (amino acids 359 to 559) is both 
highly sensitive and also highly specific. 
Moreover, the new ELISA method pro-
vides higher sensitivity and reliability for 
the detection of anti-ECM1 antibodies 
in lichen sclerosus sera than does immu-
noblotting when the full-length ECM1 
recombinant protein is used (11).
Initial screening of the lichen scle-
rosus sera disclosed that the patients’ 
autoantibodies recognize multiple 
epitopes within ECM1. More detailed 
assessment, such as selective preabsorp-
tion studies that use the recombinant 
fragment proteins, suggests that at least 
three major subsets of antigenic ECM1 
epitopes are recognized by lichen sclero-
sus autoantibodies. These subsets are (a) 
epitopes that are reactive for both the 
NH2-terminal and COOH-terminal pro-
teins (b) epitopes that are restricted to the COOH-terminus alone, 
and (c) epitopes that are restricted to just proximal to the COOH-
terminus. This finding means that screening with the recombinant 
protein that encompasses the distal second tandem repeat and the 
COOH-terminal region covers almost the entire spectrum of anti-
body reactivity against ECM1 in lichen sclerosus sera.
In essence, our study has shown that antibodies to a recombi-
nant ECM1 protein designed on amino acids 359 to 559 are detect-
able in the sera of most patients with lichen sclerosus. Further-
more, our passive-transfer experiments using neonatal mice clearly 
showed that affinity-purified lichen sclerosus IgG reactive with 
this domain can bind ECM1 in vivo and induce such skin inflam-
mation as pronounced edema, mononuclear inflammatory cell 
Figure 4
Preabsorption assays for affinity-purified lichen sclerosus sera with recombinant proteins. (A) 
Immunostaining with anti-ECM1 rabbit polyclonal antibody on normal human skin displays 
intracellular labeling in the lower epidermis, particularly in basal and suprabasal cell layers. Inset 
shows labeling of dermal blood vessels. (B) Similar staining pattern was obtained using affinity-
purified IgG fractions from ΔDs/COOH-positive lichen sclerosus sera. (C) Before immunostaining, 
the affinity-purified IgG fractions from ΔDs/COOH-positive sera were incubated with an excess 
of ΔDs/COOH recombinant. This results in a marked reduction in labeling intensity (c.f. Figure 
4B). (D) Before immunostaining, the affinity-purified IgG fractions from a dual ΔNH2-positive and 
ΔDs/COOH-positive lichen sclerosus serum were incubated with an excess of either ΔNH2 or 
ΔDs/COOH recombinants. No alteration occurred in the original labeling intensity. (E) Before 
immunostaining, the affinity-purified IgG fractions from a dual ΔNH2-positive and ΔDs/COOH-
positive sera were incubated with a mixture of both the ΔNH2 and ΔDs/COOH recombinants or 
with (F) control recombinant protein BP180 NC16A. Note the marked signal reduction in (E) but 
not in (F). Scale bar: 50 μm.
Figure 5
Quantitative analysis of IgG reactivity against the recombinant protein 
encompassing the distal COOH-terminal region of ECM1 in the sera of 
lichen sclerosus patients. Sera from 95 patients with lichen sclerosus 
(LS) and from 318 comparative control subjects (161 normal volunteers, 
70 with systemic lupus erythematosus [SLE], 72 with bullous pemphigoid 
[BP], 15 with systemic sclerosis [SSc]) were incubated with ΔDs/COOH 
recombinant protein immobilized onto an ELISA plate. Bound IgG was 
detected with alkaline phosphatase-labeled anti–human IgG antibody. 
Each serum sample was run in duplicate. The mean OD values from 
the ECM1 recombinant protein were normalized by mean OD values 
of the background immunoreactivity (against GST control protein) and 
expressed as arbitrary units (AU) on the basis of the positive and nega-
tive reference sera. Dashed line indicates a cutoff value (0.328 AU), as 
determined by receiver operative characteristic (ROC) analysis (inset). 
The area under the curve, which represents the diagnostic accuracy of 
the ELISA, was 0.919.
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infiltration, and, significantly, dilated blood vessels in the dermis. 
These findings are consistent with the pathologic hallmark of early 
lesions in lichen sclerosus skin. However, passive transfer of the 
anti-ECM1 IgG did not induce hyalinosis or scarring in the mice. 
Possible reasons for this result include not only the time course of 
the experiment but also the structural and functional interspecies 
difference between human and murine ECM1 (12). Indeed, whereas 
functional knockout of ECM1 in human subjects results in lipoid 
proteinosis, attempts to make Ecm1 knockout mice have resulted 
in embryonic lethality (J. Merregaert, personal communication). 
In addition, if the function of ECM1 in human dermis and blood 
vessels is mainly to act as a “biological glue,” for example binding 
to perlecan (13), a major heparan sulfate proteoglycan, or micro-
assembly of other components of the extracellular matrix, such 
as interstitial collagen and elastic fibers or growth factors (16), 
then perhaps additional local factors such as trauma, moisture, 
infection, or, indeed, constitutive tissue damage from antigen-spe-
cific T cells might be required to develop the full histopathologic 
characteristics of lichen sclerosus (17, 18). As for the epidermal 
pathology, the demonstration of intracellular IgG deposition in 
the mice after passive transfer raises questions about whether IgG 
can pass transmembranously. In fact, several reports demonstrate 
penetration of IgG autoantibody into living cells (19, 20). Notably 
in keratinocytes, by using passive transfer and in vitro cell culture 
systems, a series of recent investigations have also demonstrated 
that IgG autoantibodies to desmoplakin I/II, entirely intracellular 
desmosomal antigens, can get into living cells and reach the tar-
get antigens (21–23). Moreover, anti–nuclear IgG antibodies from 
patients with systemic lupus erythematosus have been shown to 
penetrate into living epithelial cells via receptor-mediated endocy-
tosis and subsequently localize to the corresponding intracellular 
target antigens (24). Considering these findings, several mecha-
nisms might be implicated in the internalization of anti-ECM1 
IgG from lichen sclerosus patients; for example (a) concentration-
dependent passive transport (b) cell surface receptor–mediated 
positive transport, or (c) a combination of these. Aside from these 
hypotheses, the inflammatory reaction induced by the anti-ECM1 
IgG is possibly capable of producing sufficient epidermal dam-
age that then allows autoantibody access to intracellular ECM1, 
followed by antibody-antigen binding. Thus, although we cannot 
conclusively define the mechanism of the intracellular in vivo IgG 
deposition for ECM1, the literature contains substantial informa-
tion to justify our data. Clearly, however, further investigations 
are needed to develop a more complete understanding of disease 
mechanism, which may also 
help explain the predomi-
nant localization of lichen 
sclerosus to genital skin in 
humans.
Our study also highlighted 
some correlation between the 
titer of anti-ECM1 antibody, 
as detected by ELISA, and the 
clinical status of the patient. 
Specifically, patients with 
more severe clinical manifes-
tations tended to have higher 
ELISA scores compared with 
those who had milder dis-
ease. More severe disease was 
usually associated with longer duration of disease, but correla-
tion between ELISA score and length of disease was only noted in 
patients with lichen sclerosus that lasted less than 1 year compared 
with disease present for more than 1 year. Nevertheless, longitudi-
nal studies that record both disease activity and ECM1 antibody 
titers over time in the same individual are necessary to address this 
problem further. Likewise, whether the development of multiple 
antigenic targets within ECM1 has any pathogenic significance 
or whether it merely represents a secondary phenomenon occur-
ring within the setting of more severe and chronic disease remains 
to be seen. One possible explanation for these multiple epitopes 
might be the phenomenon of “epitope spreading,” which is fre-
quently seen in other autoimmune skin disorders (25). Notably, 
during the course of an autoimmune condition, patient autoreac-
Table 2
Summary of ECM1-ELISA findings
 Frequency of immunoreactivityA
 n ECM1 95% CI Comparison with  Comparison with healthy 
    lichen sclerosusA control subjectsA
Lichen sclerosus 95 76 (80%) 71%–88% ... P < 0.0001
Healthy volunteers 161 7 (4.3%) 1%–7% P < 0.0001 ...
Disease control
Systemic lupus erythematosus 70 5 (7.1%) 1%–13% P < 0.0001 P = 0.88
Bullous pemphigoid 72 6 (8.3%) 2%–15% P < 0.0001 P = 0.93
Systemic sclerosis 15 2 (10.5%) 0%–27% P < 0.0001 P = 0.97
AThe cutoff value of the ELISA was determined by maximization of the Youden index.
Figure 6
Comparison between ECM1-ELISA values and clinical presentation of 
lichen sclerosus patients. Disease severity of 35 well-defined patients 
with lichen sclerosus was divided into two clinical subgroups, “severe” 
and “mild,” and analyzed with individual ELISA scores against ECM1. 
The ECM1-ELISA scores were significantly higher in patients with a 
severe clinical phenotype compared with those with a mild phenotype 
(mean ELISA score ± SD; 0.665 ± 0.216 vs. 0.425 ± 0.129, respectively; 
Mann-Whitney U test, P = 0.031). Horizontal bars indicate the mean 
ELISA values in each subgroup. In the severe group, four cases had 
longstanding disease complicated by genital skin squamous cell carci-
noma; two of whom had just genital disease (filled circles), whereas two 
others had both genital and extragenital involvement (filled squares).
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tive T cell and B cell responses do not always restrict to a unique 
immunodominant epitope, but may extend to include additional 
secondary epitopes within the same antigen.
In this study, we extended our previous observations that detec-
tion of anti-ECM1 antibodies in lichen sclerosus may serve as a 
useful diagnostic marker (11). Unfortunately, the antibodies are 
present at titers too low to be detected by conventional indirect 
immunofluorescence microscopy, as routinely performed for the 
diagnosis of such autoimmune skin blistering/scarring diseases 
as pemphigus and bullous pemphigoid (26). For lichen sclerosus 
sera or skin, immunofluorescence microscopy is usually negative 
or only faintly positive. Indeed, most other related studies have 
been unable to detect in vivo bound antibodies (apart from fibrin) 
in involved skin (27). The anti-ECM1 antibodies can be detected 
by indirect immunofluorescence microscopy after affinity purifi-
cation (11), but such an approach is not practical for routine diag-
nostic laboratories. Likewise, the anti-ECM1 autoantibodies can 
be detected by immunoblotting against epidermal extracts, but 
again, this technique is not ideally suited to routine laboratory 
activity. The novel ECM1-ELISA system now offers a practicable 
alternative means of assessment that is not only rapid but also 
more sensitive than immunoblotting. Similar technical devel-
opments of diagnostic ELISAs have already become established 
for autoimmune skin diseases such as pemphigus (28), and now 
determination of whether the ECM1-ELISA will prove equally 
useful in the diagnosis, and perhaps monitoring, of patients with 
lichen sclerosus has become possible.
Our new data linking ECM1-ELISA titer to clinical severity may 
also provide a rationale for the development of new treatment 
options for patients with lichen sclerosus that is unresponsive to 
standard regimens such as potent topical corticosteroids or sys-
temic immunosuppressants. For example, immunoadsorption 
therapy that utilizes the particular recombinant antigen could be 
valuable in efficiently removing circulating anti-ECM1 antibodies 
from the lichen sclerosus patients’ sera. Because this treatment 
is target specific, it may reduce potentially harmful and unpleas-
ant side effects associated with the use of such systemic agents as 
corticosteroids, retinoids, and cyclosporin (3, 6, 29, 30) and may 
lessen the need for surgical intervention for complications of scar-
ring or malignancy (18, 31).
In summary, this study provides the first evidence that lichen 
sclerosus IgG autoantibodies to the ECM1 glycoprotein may direct-
ly contribute to the pathophysiology of the disease. Moreover, our 
novel ELISA is useful in quantifying autoantibody reactivity, which 
potentially reflects the clinical status of patients with lichen sclero-
sus. In addition to routine clinical and skin biopsy examination, we 
Table 3
Comparison between the ECM1-ELISA scores and lichen scle-
rosus disease duration
n Duration (y) Average (y) Mean ELISA score (AU)A ± SD
5 < 1 0.8 0.377 ± 0.115
18 1 – 5 3.5 0.612 ± 0.196B
5 5 – 10 9.0 0.501 ± 0.305
11 > 10 19.1 0.577 ± 0.208B
AThe ELISA scores were expressed in arbitrary units (AU) based on 
the positive and negative reference sera, which were set to “1.0” and 
“0” OD units, respectively. BComparison with the shortest disease 
duration group (× ≤ 1 y) revealed a statistical significance (Mann-
Whitney U test, P < 0.05).
Figure 7
Passive-transfer study using affinity-purified lichen sclerosus IgG in 
neonatal BALB/c mice. (A) Intradermal injection of affinity-purified 
lichen sclerosus IgG into BALB/c mouse caused extensive erythema-
tous swelling with telangiectasie (left ear), whereas the control skin 
injected with either nonimmune human IgG exhibited no evidence of 
skin inflammation (right ear). This picture was taken at 28 days in a 
mouse that had received seven separate injections in both ears at 
days 0, 4, 8, 12, 16, 20, and 24. (B) Light microscopy of the mouse 
skin injected with affinity-purified lichen sclerosus IgG exhibited a pro-
nounced inflammatory infiltration with edema and dilated blood ves-
sels in the upper-middle dermis. The overlying epidermis showed mild 
acanthosis. (C) In contrast, the control skin injected with affinity-puri-
fied normal human IgG showed only a scanty perivascular infiltration 
in the dermis. (D) The mouse skin injected with affinity-purified lichen 
sclerosus antibodies revealed IgG deposition within the lower epider-
mis (arrows) and surrounding dilated dermal blood vessels (arrow-
heads). Asterisk indicates the injected site. Higher magnification views 
revealed an intracellular signal in basal keratinocytes and weaker 
staining in the suprabasal keratinocytes (E), as well as in the walls of 
dilated dermal blood vessels (F). (G) In contrast, the control injection 
with affinity-purified normal human IgG resulted in no immunolabeling. 
(H) At higher magnification, control injections only resulted in a non-
specific signal in the corneal layers. Scale bar: 50 μm. 
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believe that this simple ELISA assay may be helpful in the diagnosis 
and management of patients with lichen sclerosus.
Methods
Patient details. We assessed serum samples from 95 patients with 
lichen sclerosus (93 female and 2 male) and 161 healthy age/sex-
matched control subjects with no history of autoimmune diseases. 
The lichen sclerosus subjects ranged from 26 to 88 years of age. All 
had genital disease but seven also had extragenital involvement. The 
clinical diagnosis was confirmed histologically in more than 70% 
of patients. All patients had no clinical overlap with morphea or 
other autoimmune diseases, although four subjects had thyroiditis, 
of whom one also had vitiligo and pernicious anemia, and one other 
had vitiligo. Nearly all patients were applying topical potent or ultra-
potent steroid ointments to their lichen sclerosus skin at the time 
of serum sampling. Of the lichen sclerosus sera, 64/95 samples had 
been shown previously to react with full-length ECM1 recombinant 
protein on immunoblotting (11). For clinical evaluation, detailed 
information was available from 35 lichen sclerosus patients, who 
were then classified as either “severe” or “mild.” Given the lack of 
published criteria for determining the actual clinical severity of 
lichen sclerosus, the severe group (n = 17) comprised those patients 
with disease complicated by genital skin squamous cell carcinoma 
(n = 4), two of whom had extragenital as well as genital lichen sclero-
sus, and 13 other patients with either active enlarging skin plaques 
or disease that was difficult to control by application of topical 
steroids or that frequently relapsed. The mild group (n = 18) com-
prised patients with genital lichen sclerosus whose condition was 
adequately controlled by topical steroids or in whom the disease was 
inactive. Unfortunately, the cohort did not include any patients with 
just extragenital lichen sclerosus. In addition, apart from the disease 
severity that was the basis of two groups, disease duration was used 
to divide the patients into four groups consisting of those who had 
the disease less than 1 year, 1 to 5 years, 5 to 10 years, and more 
than 10 years. All clinical information was accurately recorded at the 
same time as the sera were taken.
As disease controls, archival serum samples were chosen ran-
domly from 157 subjects with other autoimmune sclerosing or 
basement-membrane diseases. These samples comprised systemic 
sclerosis (n = 15), systemic lupus erythematosus (n = 70), and bul-
lous pemphigoid (n = 72). These control diseases were diagnosed 
by clinical criteria, routine histology, and immunopathology.
All serum samples were collected from patients attending out-
patient clinics at St. Thomas’ Hospital (London, United King-
dom), Churchill Hospital (Oxford, United Kingdom), Ashford 
Hospital (Ashford, United Kingdom), and St, Peter’s Hospital 
(Chertsey, United Kingdom). Samples were anonymized and 
the underlying diagnosis was concealed from the investigators 
performing the experiments. Local ethics committee approval 
was obtained for all parts of the study. All serum samples were 
stored at 20°C until assayed.
DNA. The nucleotide and amino acid sequences of human ECM1 
cDNA were based on previously published data (13).
Construction of ECM1 cDNA fragments. We have recently con-
structed an E. coli transfer vector that contains the full-length 1.8-
kb ECM1 cDNA (11). This construct was used to make a series of 
truncated recombinant fragments that spanned almost the entire 
ECM1 sequence (see Figure 1).
To generate the ΔNH2 clone, the original full-length ECM1 vec-
tor was digested with PvuII, and the excised cDNA fragment corre-
sponding to the NH2-terminal region (nucleotides 94 to 615) was 
ligated in-frame into the prokaryotic GST fusion vector, pGEX-
4T-3 (Amersham Pharmacia Biotech, Buckinghamshire, United 
Kingdom), at SmaI restriction sites, with correct orientation.
For construction of clones ΔPx/COOH and ΔS/COOH, the 
original ECM1 vector was first digested with BsaI, which resulted 
in generation of two cDNA fragments, Px/COOH (nucleotides 
616 to 1438) and S/COOH (nucleotides 1439 to 1709). After 
blunt-ended digestion with Klenow enzyme, these fragments were 
subcloned independently into pBlueScript vector (Stratagene, La 
Jolla, California, USA) at an EcoRV site. The Px/COOH fragment 
was then inserted in-frame into pGEX-4T-3 vector at SalI and 
NotI sites, whereas the S/COOH fragment was introduced into 
the pGEX-4T-2 vector at EcoRI and NotI sites.
For construction of the ΔS/ex7 clone, the Px/COOH fragment 
obtained above was excised with BamHI and PvuII, blunt-ended, 
and inserted with correct orientation into the pGEX-4T-3 vector 
at a SmaI site.
The ΔDs/COOH clone was prepared by digesting the original 
full-length ECM1 vector with PvuII and NotI, followed by relegat-
ing in-frame into the pGEX-4T-2 vector at SmaI and NotI sites.
These procedures all fuse the GST tag at the NH2-terminus of the 
recombinant proteins. All the cDNA constructs were sequenced to 
confirm the identity and fidelity of the subcloning steps.
Induction of recombinant protein. The ECM1 cDNA clones obtained 
above were transformed independently into E. coli strain BL21Star 
(DE3) (Invitrogen, Groningen, The Netherlands) and inoculated 
into liter cultures of 2xYT medium containing 50 μg/ml ampi-
cillin, followed by protein induction using 0.5 to 1 mM isopro-
pyl β-D-thiogalactopyranoside (Amersham Pharmacia Biotech). 
After the protein extraction, the recovered recombinant protein 
was purified by affinity chromatography using a glutathione sep-
harose 4B column (Amersham Pharmacia Biotech). The protein 
concentration was determined by Bradford protein assay (Bio-Rad, 
Hercules, California, USA).
Affinity purification and preabsorption of patients’ sera. IgG fractions 
from lichen sclerosus patients’ sera (selected on the basis of posi-
tive recombinant ECM1 protein immunoblots) were affinity puri-
fied using Protein G-Sepharose columns (Amersham Pharmacia 
Biotech). After washing with ice-cold PBS (pH7.5), bound IgGs 
were eluted with 0.1 mol/l glycine (pH 2.5) and neutralized imme-
diately with 1 mol/l Tris/HCl (pH 9.0). The fractionated samples 
were dialyzed with PBS at 4°C overnight and concentrated by Cen-
tricon-10 columns (Amicon, Gloucestershire, United Kingdom). 
The resultant IgGs were incubated overnight at 4°C with an equal 
amount of either the recombinant ECM1 proteins or the control 
proteins, GST or BP180 NC16a (the latter representing the anti-
genic epitope most frequently recognized in sera from patients 
with the common autoimmune blistering skin disease, bullous 
pemphigoid) (32), followed by precipitation. IgG fractions from 
each of three normal human subjects were prepared in a similar 
manner and used for control experiments. The supernatants were 
collected and tested for any residual immunoreactivity on normal 
human skin sections and ELISA.
Immunohistochemistry. Indirect immunofluorescence was per-
formed using standard methods, as described previously (33). 
Briefly, 5-μm frozen sections of normal human skin were incu-
bated at 37°C for 1 h with affinity-purified IgGs from patients’ 
sera (1:100 dilution in PBS), control IgG from normal human sera 
(1:100 dilution in PBS), or anti-ECM1 rabbit polyclonal antibody 
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in combination with or without the preabsorption step, followed 
by FITC-labeled anti–human IgG antibody (Dako, Cambridgeshire, 
United Kingdom). Details of the ECM1 antibody (raised against 
the COOH-terminal 17 amino acids of human ECM1) have been 
published elsewhere (11).
Immunoblotting. The ECM1-GST fusion proteins were separat-
ed on 12% nongradient SDS-polyacrylamide gels and visualized 
by Coomassie blue staining or immunoblotting with horserad-
ish peroxidase-labeled rabbit anti-GST antibody (Amersham 
Pharmacia Biotech), to verify molecular weight and quality of 
the protein purification.
For serum immunoblotting, equivalent amounts of each recom-
binant ECM1 protein loaded on the gels were transblotted onto 
nitrocellulose membranes (Bio-Rad). After blocking with Tris-
buffered saline (TBS)/3% skimmed milk, the membranes were cut 
into small strips and incubated overnight at 4°C with the patients’ 
sera (1:20 dilution with TBS/3% skim milk). The membrane strips 
were then reacted with alkaline phosphatase–labeled secondary 
antibodies (Dako), followed by signal development using nitro-
blue tetrazolium substrate (Bio-Rad).
ECM1 ELISA. Optimal conditions for the ELISA method were 
established by various chessboard titrations following technical 
protocols published elsewhere (34).
The recombinant proteins were immobilized on 96-well micro-
titer plates (MaxiSorp; Nunc, Roskilde, Denmark) by coating 
each well with either 0.5 μg of ΔDs/COOH or a molar equivalent 
amount of the control GST protein in 100 μl of 0.1 M carbonate-
bicarbonate buffer (pH 9.8) at 4°C overnight. All procedures were 
performed at room temperature, except the antigen coating. After 
each step, the wells were washed four times with 50 mM Tris/HCl 
(pH 7.5) containing 0.05% Tween 20 (TBS-T). The ELISA plates 
were incubated for 2 h with 200 μl of a blocking buffer consist-
ing of 3% bovine serum albumin (fraction V; Sigma-Aldrich, St. 
Louis, Missouri, USA) in TBS-T. Sera were diluted 1:100 in the 
blocking buffer, and then added to each well in duplicate. After 
incubating for 2 h, the bound IgG were detected with 100 μl of 
alkaline phosphatase–conjugated anti–human IgG rabbit F(ab′)2 
polyclonal antibody (Dako) diluted 1:4,000 in TBS-T, followed by 
colorimetric assay using p-nitrophenylphosphate (Sigma-Aldrich). 
The color development was stopped by 3M NaOH. The optical 
density (OD) was measured at 405 nm by an automated plate 
reader (Revelation; Dynex Technologies, Chantilly, Virginia, USA) 
according to kinetic measurements so that the ODs of a positive 
reference sera or anti-ECM1 antibody reached at least “1.0.” In 
each serum sample, the background reactivity against the control 
GST protein was subtracted from the mean OD values with ΔDs/
COOH. The antibody concentrations obtained were expressed in 
AUs based on the positive and negative reference sera, which were 
set to “1.0” and “0” OD units, respectively. The reference sera and 
anti-ECM1 antibody were always used to correct interplate/intra-
plate variability for this assay.
Statistics. Statistical analysis was performed using SPSS version 
11.0 (SPSS, Chicago, Illinois, USA). ROC curves were used to 
evaluate the ability of the ELISA to detect specific autoantibodies 
against the ΔDs/COOH recombinant protein. The AUC index was 
reported with the relative 95% CI to compare ECM1 seroreactiv-
ity between lichen sclerosus and all comparative control groups. 
The Youden index was used to select the best cutoff values for the 
ELISA. To assess the reproducibility of the ELISA results, coeffi-
cients of variance were calculated for reference lichen sclerosus and 
normal control sera. Comparison of the ELISA results between 
patient and control groups was statistically analyzed using Mann-
Whitney’s nonparametric, unpaired, two-tailed test and Pearson’s 
correction test or Fisher’s exact probability test when more than 
20% of the expected values were lower than 5.
Passive-transfer study. Neonatal BALB/c mice (age, 24 to 36 h; body 
weight, 1.4 to 1.8 g) were used for passive-transfer experiments (32, 
35). The ears of the mice were injected intradermally with either (a) 
affinity-purified IgG from any one of six lichen sclerosus patients 
(b) affinity-purified IgG from any of three normal human subjects 
(c) PBS, or (d) anti-ECM1 polyclonal antibody. In individual mice, 
the left and right ear was injected with a different solution. For 
the IgG injections, the amount injected was 0.5 to 1.0 mg of total 
IgG per g of body weight. Injections were given every 4 days up to 
24 days. All mice were physically examined daily and skin biopsies 
were taken at day 0, day 4, and day 28. Each mouse only under-
went one biopsy from each ear. The total number of mice used for 
these experiments was 27. All skin samples were examined by light 
microscopy (H&E staining) and by immunofluorescence micros-
copy for IgG deposition.
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